Baxter International, Inc. Presents Efficacy And Safety Data On VIVIA Haemodialysis System At ERA-EDTA Congress
Published: Jun 03, 2014
AMSTERDAM--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis (HD) system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process (market approval) in Europe, December 2013.
Help employers find you! Check out all the jobs and post your resume.